Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

BAYER PORTUGAL, LDA

NIF 500043256
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €6,574,043 77 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €6,574,043 77 contracts
A2 · Late Publication €11,115,731,132 3,820 contracts
Contract published to BASE more than 10 days after the signing date
LOW €11,115,731,132 3,820 contracts
A5 · Threshold Splitting €82,256,784 136 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €82,256,784 136 contracts
A6 · Low Competition €11,737,288 44 contracts
Only one bidder participated in a competitive procedure
MEDIUM €11,737,288 44 contracts
A9 · Price Overrun €14,105 3 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €13,405 2 contracts
MEDIUM €700 1 contracts
A9 · Abnormal Price Reduction €14,749,099,802 2,185 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €14,749,099,802 2,185 contracts
C3 · Missing Mandatory Fields €8,833,669 114 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €8,833,669 114 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

457
€552,963,731
63
€549,439,855
196
€536,226,488
70
€515,258,633
85
€508,017,127
121
€506,797,562
76
€497,555,224
257
€486,751,868
475
€484,969,390
58
€483,424,218
100
€468,727,000
323
€460,947,237
179
€455,751,106
58
€453,568,013
54
€445,895,449
39
€443,768,959
66
€442,291,057
309
€438,538,940
56
€429,461,202
55
€422,786,245
Page 1 of 4 · 73 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 44 contracts

EAD20250029 - CONSUMIVEIS PARA O INJETOR AVANTA
PT · 11288173 · Ajuste Direto Regime G...
A6 · Low Competition
€12,624 2025-03-17
Fornecimento de Iopromida ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 11288855 · Ajuste Direto Regime G...
A6 · Low Competition
€42,000 2025-03-17
2025001986 – Aquisição de medicamentos
PT · 11275531 · Ajuste Direto Regime G...
A6 · Low Competition
€80,704 2025-03-11
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11214492 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€121,984 2025-02-06
CONSUMÍVEIS PARA EQUIPAMENTO AVANT
PT · 11239203 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€93,609 2025-02-05
DAMOCTOCOG ALFA PEGOL PÓ SOL INJ FR IV
PT · 11228547 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€365,656 2025-01-15
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11200641 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€121,984 2025-01-02
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11170331 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€121,984 2025-01-02
040100722025-1174/2024-Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11203865 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€6,414 2024-12-27
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11300734 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€8,979 2024-12-26
2024010518 – Aquisição de medicamentos
PT · 11073061 · Ajuste Direto Regime G...
A6 · Low Competition
€33,395 2024-12-09
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11158149 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€6,414 2024-12-04
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11316236 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields +1
€2,886 2024-11-26
Aquisição de Darolutamida ao Abrigo do AQ 2023/491
PT · 11044243 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€33,395 2024-11-13
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11210270 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€320 2024-11-11
Ajuste direto para aquisição de I1005 - Interferão Beta-1B [8 M.U.I./ML; 1,2 ML; pó sol inj; Frs] e C217- Ciproterona [100 mg/ ml; 3 ml; sol. inj; amp]
PT · 11158754 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€7,696 2024-11-11
Prestação de serviços de aluguer de injectora para Ressonância Magnética para o Serviço de Radiologia
PT · 11009307 · Consulta Prévia
A6 · Low Competition
€10,500 2024-11-05
Ajuste direto para aquisição de L1015 - Levonorgestrel [52mg].
PT · 10994380 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€13,378 2024-10-09
Aquisição de Aflibercept 40 mg/ml Sol inj Fr 100 µl Intravítreo AQ 2024_782 - nova qt
PT · 10903269 · Ao abrigo de acordo-qu...
A6 · Low Competition
€198,541 2024-09-05
Amidot meglu660mg/ml+Amidotri sód100mg/ml 100ml IAmnioIArtIUteIntralesIVIVesGE; e Aflibercept 114.3 mg/ml Sol inj Fr 0.263 ml Intravítreo.
PT · 10903244 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€4,978 2024-09-04
DAROLUTAMIDA - 3 MESES
PT · 10897375 · Ao abrigo de acordo-qu...
A6 · Low Competition
€16,697 2024-09-02
BEAD20240383 - AQUISIÇÃO DE REGORAFENIB
PT · 10886229 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction A6 · Low Competition
€11,959 2024-08-26
Aquisição Exclusiva de AFLIBERCEPT
PT · 10950915 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€8,303 2024-08-23
J1/2444/2024 - AFLIBERCEPT 114,3 MG/ML SOL INJ FRS 70uL INTRAVITREO
PT · 10862830 · Ajuste Direto Regime G...
A6 · Low Competition
€25,601 2024-08-02
LAROTRECTINIB 20 MG/ML SOL ORAL FR 50 ML
PT · 11002844 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€15,688 2024-07-26
C/ BASE NO CPA 2023_491
PT · 10979082 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€397,957 2024-07-11
MEIOS DE CONTRASTE RADIOLOGICO - 2º SEMESTRE
PT · 10756763 · Ao abrigo de acordo-qu...
A6 · Low Competition
€87,982 2024-06-06
BEAD20240281 - AQUISIÇÃO DE DICLORETO DE RÁDIO
PT · 10728101 · Ao abrigo de acordo-qu...
A6 · Low Competition
€23,921 2024-05-21
LAROTRECTINIB 20 MG/ML SOL ORAL FR 50 ML
PT · 10984205 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€15,688 2024-05-06
2024002540 – Aquisição de medicamentos
PT · 10658891 · Ajuste Direto Regime G...
A6 · Low Competition
€181,523 2024-04-09
Aquisição de Iopromida 370 mg/ml Sol inj Fr 100 ml EV ao abrigo do Acordo Quadro 2022/56 para o ano 2024
PT · 10838071 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€0 2024-04-04
241G000097 - DAMOCTOCOG ALFA PEGOL, PARA 1.ºsem/2024
PT · 10624893 · Ajuste Direto Regime G...
A6 · Low Competition
€735,077 2024-03-19
LAROTRECTINIB 100MG Caps
PT · 10631978 · Ajuste Direto Regime G...
A6 · Low Competition
€13,177 2024-03-15
Aquisição do medicamento DAMOCTOCOG ALFA PEGOL 1000 U.I. PÓ SOL INJ FR IV
PT · 10600450 · Ajuste Direto Regime G...
A6 · Low Competition
€36,920 2024-03-01
Aquisição de Aflibercept
PT · 10623714 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€22,690 2024-02-26
Fornecimento de Iloprost 20 µG/Ml ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 10613856 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€35,053 2024-02-23
EX/845/2024 – LAROTRECTINIB 100MG CÁPS
PT · 10884687 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€57,104 2024-02-16
AQUISIÇÃO DE INTERFERON BETA 1B 8 MILHOES SC/IM AMPOLAS AO ABRIGO DO ACORDO QUADRO 2021/006 DOS SPMS, EPE
PT · 10793681 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€11,545 2024-02-09
MEDICAMENTOS EXCLUSIVOS - BAYER PORTUGAL
PT · 10581595 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€338,832 2024-02-06
AQUISIÇÃO DO MEDICAMENTO DAMOCTOCOG ALFA PEGOL DE FORNECIMENTO EXCLUSIVO DO LABORATÓRIO BAYER PORTUGAL: ANO 2024
PT · 10542542 · Ajuste Direto Regime G...
A6 · Low Competition
€90,355 2024-02-01
Aquisição de COMPLEXO B + BIOTINA COMP para 2024
PT · 10656833 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€7,787,640 2024-01-29
241G000135-LEVONORGESTREL D.I.U 52 MG .
PT · 10525407 · Ajuste Direto Regime G...
A6 · Low Competition
€3,675 2024-01-26
31/855/2024 - Medicamentos Iopromida ( MG/ ML; SOl INJ )
PT · 10649581 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€0 2024-01-25
61/362/2024 - Medicamentos varios
PT · 10691004 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€532,458 2024-01-18
Overview
Total Value Won
€14,942,347,800
Contracts Won
5,502
Score 186560 · CRITICAL RISK
NIF
500043256
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • D.G. [P-e518]
    Gerente
  • E.N. [P-f1b0]
    Administrador
  • F.G. [P-c46d]
    Administrador
  • F.B. [P-3e7d]
    Presidente
  • J.S. [P-6d9b]
    Gerente
  • J.M. [P-74b5]
    Fiscal Único
  • P.A. [P-4562]
    Fiscal Único
  • B.A. [P-abe9]
    Sócio
  • B.B. [P-da6a]
    Sócio
  • B.G. [P-343d]
    Sócio
  • B.G. [P-d8c5]
    Sócio
  • B.H. [P-4485]
    Sócio
  • B.H. [P-5d79]
    Sócio
  • E.N. [P-280e]
    Administrador
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned